dc.contributor.author |
Ng'ang'a, Zipporah W. |
|
dc.contributor.author |
Nyamache, A. K. |
|
dc.contributor.author |
Waihenya, R. |
|
dc.contributor.author |
Muigai, A. W. |
|
dc.contributor.author |
Khamadi, S. A. |
|
dc.date.accessioned |
2014-12-03T08:49:41Z |
|
dc.date.available |
2014-12-03T08:49:41Z |
|
dc.date.issued |
2011 |
|
dc.identifier.citation |
East Afr Med J. 2011 Jan;88(1):4-8. |
en_US |
dc.identifier.uri |
http://www.ncbi.nlm.nih.gov/pubmed/24968596 |
|
dc.identifier.uri |
http://hdl.handle.net/123456789/303 |
|
dc.description.abstract |
OBJECTIVE:
To evaluate the extent of HIV-1 drug resistance among drug naive Kenyan individuals.
DESIGN:
Cross-sectional study.
SETTING:
Kenya Medical Research Institute HIV laboratory Nairobi, Kenya.
SUBJECTS:
A total of seventy eight HIV-1 positive drug naive subjects randomised from five Kenyan provincial hospitals between April and June 2004.
RESULTS:
A major non-nucleoside reverse transcriptase (NNRTI) an associated mutation was found in one patient (1.3%). NNRTI associated resistance mutations were present at amino acid codon sites G98A (2.56%); K103E (1.3%) and L100F (3.57%) prevalences. Baseline resistance may compromise the response to standard NNRTI-based first-line ART in 1.3 % of the study subjects.
CONCLUSION:
This indicates in general, that drug resistance among HIV-1 positive drug naive individual is at low thresholds (1.3%) but the problem could be more serious than reported here. Continuous resistance monitoring is therefore warranted to maintain individual and population-level ART effectiveness. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Kenya Medical Association |
en_US |
dc.title |
Reverse transcriptase inhibitors drug resistance mutations in drug-naive HIV type 1 positive Kenyans. |
en_US |
dc.type |
Article |
en_US |